Search

Your search keyword '"Kawai, Moeko"' showing total 14 results
Start Over Author "Kawai, Moeko"
14 results on '"Kawai, Moeko"'

1. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

Author

Mukai, Ryo, Kataoka, Keiko, Tanaka, Koji, Miyara, Yasunori, Maruko, Ichiro, Nakayama, Makiko, Watanabe, Yuto, Yamamoto, Akiko, Wakatsuki, Yu, Onoe, Hajime, Wakugawa, Sorako, Terao, Nobuhiro, Hasegawa, Taiji, Kawai, Moeko, Maruko, Ruka, Itagaki, Kanako, Honjo, Jyunichiro, Okada, Annabelle A., Mori, Ryusaburo, Koizumi, Hideki, Iida, Tomohiro, and Sekiryu, Tetsuju

Published
2024
Full Text
View/download PDF

2. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

Author

Kataoka, Keiko, Itagaki, Kanako, Hashiya, Nozumu, Wakugawa, Sorako, Tanaka, Koji, Nakayama, Makiko, Yamamoto, Akiko, Mukai, Ryo, Honjyo, Jyunichiro, Maruko, Ichiro, Kawai, Moeko, Miyara, Yasunori, Terao, Nobuhiro, Wakatsuki, Yu, Onoe, Hajime, Mori, Ryusaburo, Koizumi, Hideki, Sekiryu, Tetsuju, Iida, Tomohiro, and Okada, Annabelle A.

Published
2024
Full Text
View/download PDF

4. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan

Author

Mukai, Ryo, Kataoka, Keiko, Tanaka, Koji, Miyara, Yasunori, Maruko, Ichiro, Nakayama, Makiko, Watanabe, Yuto, Yamamoto, Akiko, Wakatsuki, Yu, Onoe, Hajime, Wakugawa, Sorako, Terao, Nobuhiro, Hasegawa, Taiji, Hashiya, Nozomu, Kawai, Moeko, Maruko, Ruka, Itagaki, Kanako, Honjo, Jyunichiro, Okada, Annabelle A., Mori, Ryusaburo, Koizumi, Hideki, Iida, Tomohiro, and Sekiryu, Tetsuju

Published
2023
Full Text
View/download PDF

6. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study

Author

Tanaka, Koji, Koizumi, Hideki, Tamashiro, Tamaki, Itagaki, Kanako, Nakayama, Makiko, Maruko, Ichiro, Wakugawa, Sorako, Terao, Nobuhiro, Onoe, Hajime, Wakatsuki, Yu, Kasai, Akihito, Ogasawara, Masashi, Shintake, Hiroaki, Sugano, Yukinori, Yamamoto, Akiko, Kataoka, Keiko, Hasegawa, Taiji, Izumi, Takahiko, Kawai, Moeko, Maruko, Ruka, Sekiryu, Tetsuju, Okada, Annabelle A., Iida, Tomohiro, and Mori, Ryusaburo

Published
2022
Full Text
View/download PDF

7. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Author

Tamashiro, Tamaki, Tanaka, Koji, Itagaki, Kanako, Nakayama, Makiko, Maruko, Ichiro, Wakugawa, Sorako, Terao, Nobuhiro, Onoe, Hajime, Wakatsuki, Yu, Ogasawara, Masashi, Sugano, Yukinori, Yamamoto, Akiko, Kataoka, Keiko, Izumi, Takahiko, Kawai, Moeko, Mori, Ryusaburo, Sekiryu, Tetsuju, Okada, Annabelle A., Iida, Tomohiro, and Koizumi, Hideki

Published
2022
Full Text
View/download PDF

11. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study.

Author

Maruko, Ichiro, Okada, Annabelle A., Iida, Tomohiro, Hasegawa, Taiji, Izumi, Takahiko, Kawai, Moeko, Maruko, Ruka, Nakayama, Makiko, Yamamoto, Akiko, Koizumi, Hideki, Tamashiro, Tamaki, Terao, Nobuhiro, Wakugawa, Sorako, Mori, Ryusaburo, Onoe, Hajime, Tanaka, Koji, Wakatsuki, Yu, Itagaki, Kanako, Kasai, Akihito, and Ogasawara, Masashi

Subjects
EYE inflammation, JAPANESE people, MACULAR degeneration, RETINAL vein occlusion, VASCULAR endothelial growth factors, INTRAVITREAL injections, EYE diseases
Abstract

Graph Dear Editor, We report short-term data on the development of intraocular inflammation (IOI) after intravitreal brolucizumab injection for exudative age-related macular degeneration (AMD) in Japanese patients in this letter. However, among 101 Japanese patients enrolled in the HAWK study, the rates were 2- to 3-fold higher; IOI in 12.9%, retinal vasculitis in 9.9%, and retinal vascular occlusion in 4.95% [[5]]. Of 127 eyes, 12 (9.4%) developed IOI consisting of anterior chamber cells and/or vitreous cells, with retinal vasculitis documented in 4 eyes (3.1%) and retinal vascular occlusion in 2 eyes (1.6%) (Table 1). [Extracted from the article]

Published
2021
Full Text
View/download PDF

12. Use of Explainable AI on Slit-lamp Images of Anterior Surface of eyes to Diagnose Allergic Conjunctival Diseases

Author

Yonehara, Michiko, Nakagawa, Yuji, Ayatsuka, Yuji, Hara, Yuko, Shoji, Jun, Ebihara, Nobuyuki, Inomata, Takenori, Huang, Tianxiang, Nagino, Ken, Fukuda, Ken, Kishimoto, Tatsuma, Sumi, Tamaki, Fukushima, Atsuki, Fujishima, Hiroshi, Kawai, Moeko, Takamura, Etsuko, Uchio, Eiichi, Namba, Kenichi, Koyama, Ayumi, Haruki, Tomoko, Sasaki, Shin-ich, Shimizu, Yumiko, and Miyazaki, Dai

Abstract

Artificial intelligence (AI) is a promising new technologythat has the potential of diagnosingallergic conjunctival diseases (ACDs). However, its development is slowed by the absence of a tailored image database and explainable AI models. Thus, the purpose of this study was to develop an explainable AI model that can not only diagnose ACDs but also present the basis for the diagnosis.

Published
2024
Full Text
View/download PDF

14. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study.

Author

Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Maruko R, Nakayama M, Yamamoto A, Koizumi H, Tamashiro T, Terao N, Wakugawa S, Mori R, Onoe H, Tanaka K, Wakatsuki Y, Itagaki K, Kasai A, Ogasawara M, Sekiryu T, Shintake H, and Sugano Y

Subjects
Humans, Inflammation, Japan epidemiology, Antibodies, Monoclonal, Humanized adverse effects, Macular Degeneration diagnosis, Macular Degeneration drug therapy
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results